Literature DB >> 15496401

Tetrameric oligomerization mediates transcriptional repression by the BRCA1-dependent Kruppel-associated box-zinc finger protein ZBRK1.

Wei Tan1, Seokjoong Kim, Thomas G Boyer.   

Abstract

The Kruppel-associated box (KRAB)-zinc finger protein ZBRK1 has been implicated in the transcriptional regulation of DNA damage-response genes that function in cell growth control and survival. Recently, we described a novel BRCA1-dependent C-terminal transcriptional repression domain (CTRD) within ZBRK1, the mode of repression of which is functionally distinguishable from that of the N-terminal KRAB repression domain within ZBRK1. The identification of BRCA1 binding-competent but repression-defective CTRD mutants further revealed that BRCA1 binding is necessary, but not sufficient, for ZBRK1 CTRD function. During an unbiased search for possible co-regulators of the CTRD, we identified ZBRK1 itself, suggesting that ZBRK1 can oligomerize through its CTRD. Herein we explore the physical and functional requirements for ZBRK1 oligomerization in ZBRK1-directed transcriptional repression. Protein interaction analyses confirmed that ZBRK1 can homo-oligomerize both in vitro and in vivo and further mapped the ZBRK1 oligomerization domain to the CTRD C terminus. Biochemical analyses, including protein cross-linking and gel filtration chromatography, revealed that ZBRK1 homo-oligomers exist as tetramers in solution. Functionally, ZBRK1 oligomerization facilitates ZBRK1-directed transcriptional repression through ZBRK1 response elements; requirements for oligomerization-dependent repression include the ZBRK1 CTRD and KRAB repression domains but not the DNA binding activity of ZBRK1. These observations suggest that higher order oligomers of ZBRK1 may assemble on target ZBRK1 response elements through both protein-DNA and CTRD-dependent protein-protein interactions. These findings thus reveal an unanticipated dual function for ZBRK1 in both DNA binding-dependent and -independent modes of transcriptional repression and further establish the CTRD as a novel protein interaction surface responsible for directing homotypic and heterotypic interactions necessary for ZBRK1-directed transcriptional repression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496401     DOI: 10.1074/jbc.M410926200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility.

Authors:  Badan Sehrawat; Malinee Sridharan; Sunita Ghosh; Paula Robson; Carol E Cass; John R Mackey; Russell Greiner; Sambasivarao Damaraju
Journal:  Hum Genet       Date:  2011-03-19       Impact factor: 4.132

2.  ZBRK1, a novel tumor suppressor, activates VHL gene transcription through formation of a complex with VHL and p300 in renal cancer.

Authors:  Ke Chen; Gan Yu; Kiranmai Gumireddy; Anping Li; Weimin Yao; Lu Gao; Shuliang Chen; Jun Hao; Ji Wang; Qihong Huang; Hua Xu; Zhangqun Ye
Journal:  Oncotarget       Date:  2015-03-30

3.  Five zinc finger protein 350 single nucleotide polymorphisms and the risks of breast cancer: a meta-analysis.

Authors:  Yu Fan Zeng; Jianfeng Sang
Journal:  Oncotarget       Date:  2017-10-07

Review 4.  KRAB-ZFP Transcriptional Regulators Acting as Oncogenes and Tumor Suppressors: An Overview.

Authors:  Joanna Sobocińska; Sara Molenda; Marta Machnik; Urszula Oleksiewicz
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

5.  Correlation between ZBRK1/ZNF350 gene polymorphism and breast cancer.

Authors:  Jun Wu; Alibiati Eni; Eliar Roussuri; Binlin Ma
Journal:  BMC Med Genomics       Date:  2021-01-06       Impact factor: 3.063

6.  Easy Expression and Purification of Fluorescent N-Terminal BCL11B CCHC Zinc Finger Domain.

Authors:  Anne Susemihl; Felix Nagel; Piotr Grabarczyk; Christian A Schmidt; Mihaela Delcea
Journal:  Molecules       Date:  2021-12-14       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.